Specifically, when communicating to resected EGFR-mutated NSCLC patients about the possibility of adjuvant chemotherapy before osimertinib, the main points to highlight and discuss with them are as follows: the approximate recurrence rate of disease, the absolute reduction in risk of death given by osimertinib alone, the further presumed absolute risk reduction given by the administration of chemotherapy before osimertinib, the risk of severe adverse events correlated with chemotherapy, and the impact on quality of life of chemotherapy. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.